Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Trevor Banka

Adult Reconstructive Orthopaedic Surgery Detroit, MI Medical Doctor

NPI 1508069618 CMS profile 68206

2799 W Grand Blvd, Cfp-6, Detroit, MI 48202

Open in the dashboard

General payments

$339,324

417 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trevor Banka of Detroit, MI is reported in the CMS Open Payments database as having received $339,324 across 417 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,498 16
2024 General $41,740 45
2023 General $77,716 78
2022 General $79,567 121
2021 General $79,494 100
2020 General $34,664 38
2019 General $9,645 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trevor Banka
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Trevor Banka were reported at $16,498. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Trevor Banka Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $9,645 $1,416 $292–$9,336 $163
2020 $34,664 $647 $141–$6,474 $114
2021 $79,494 $1,073 $211–$6,497 $132
2022 $79,567 $1,217 $236–$6,299 $149
2023 $77,716 $1,082 $246–$6,818 $160
2024 $41,740 $1,575 $323–$8,944 $164
2025 $16,498 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $339,028 411 payments
  2. Medical Device Business Services, Inc. $127 1 payment
  3. Medtronic USA, Inc. $94 1 payment
  4. Stryker Corporation $34 2 payments
  5. DePuy Synthes Sales Inc. $22 1 payment
  6. Sanara MedTech Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $266,163 168 payments
  2. Education $47,738 28 payments
  3. Travel and Lodging $19,976 105 payments
  4. Food and Beverage $5,447 116 payments
Products named General payments · program years 2019–2025
  1. ROSA $180,738 196 payments
  2. ROSA-Knee Knees $70,985 88 payments
  3. ROSA-Knee Knees $32,385 34 payments
  4. G7 $18,112 19 payments
  5. Taperloc $16,875 5 payments
  6. Persona Knees $12,911 17 payments
  7. Persona Knees $4,000 4 payments
  8. NexGen $4,000 4 payments
  9. Vanguard $4,000 4 payments
  10. PD-Knee-New Product $1,000 1 payment
  11. Other $2,252 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,092

Median for Orthopedic Surgery: 203

Drug cost

$6,436

Median for Orthopedic Surgery: $1,433

Branded share of claims

2.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $2,299
Meloxicam Generic 281 $1,024
Methocarbamol Generic 146 $668
Oxycodone Hcl Generic 128 $574
Tizanidine Hcl Generic 39 $424
Diclofenac Sodium Generic 11 $329
Amoxicillin Generic 287 $282
Celecoxib Generic 16 $276
Dexamethasone Generic 48 $227
Ssd Silver Sulfadiazine Brand 11 $136

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$202,340

Medicare's payments for the services billed

Medicare patients

371

Average age 72

Services billed

795

245 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 29%
Depression 26%
Ischemic heart disease 24%
Chronic kidney disease 18%
Osteoporosis 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

417 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record